Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AC Immune (ACIU : NSDQ)

• Company Description    AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $3.15 Daily Weekly Monthly 20 Day Moving Average: 105,142 shares Shares Outstanding: 83.48 (millions) Market Capitalization: $262.96 (millions) Beta: 0.86 52 Week High: $8.64 52 Week Low: $2.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.32% -6.89% 12 Week -16.00% -7.66% Year To Date -36.36% -22.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL EPFL INNOVATION PARK BUILDING B - 1015 LAUSANNE,V8 1015 CHE ph: 41-21-345-9121 fax: 41-21-345-9120 ir@acimmune.com http://www.acimmune.com

• General Corporate Information    Officers Andrea Pfeifer - Chief Executive Officer and Director Douglas Williams - Chairman and Director Joerg Hornstein - Chief Financial Officer Thomas Graney - Director Werner Lanthaler - Director Peer Information AC Immune (CORR.) AC Immune (RSPI) AC Immune (CGXP) AC Immune (BGEN) AC Immune (GTBP) AC Immune (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H00263105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 83.48 Most Recent Split Date: (:1) Beta: 0.86 Market Capitalization: $262.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.99 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.13 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 10.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -35.82 12/31/21 - -36.04 09/30/21 - -36.35 ROA 03/31/22 - -32.01 12/31/21 - -32.22 09/30/21 - -32.65 Current Ratio 03/31/22 - 14.87 12/31/21 - 10.12 09/30/21 - 13.74 Quick Ratio 03/31/22 - 14.87 12/31/21 - 10.12 09/30/21 - 13.74 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -7,453.11 Book Value 03/31/22 - 2.78 12/31/21 - 3.49 09/30/21 - 2.69 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©